bluebird bio, Inc. (NASDAQ:BLUE) Files An 8-K Other Events
Item 8.01Other Events.
On January 8, 2019, bluebird bio, Inc. conducted an investor presentation at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California.A copy of the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits
bluebird bio, Inc. Exhibit
EX-99.1 2 blue-ex991_14.htm EX-99.1 blue-ex991_14.pptx.htm READY TO RECODE 37th Annual J.P. Morgan Healthcare Conference January 8,…
To view the full exhibit click here
About bluebird bio, Inc. (NASDAQ:BLUE)
bluebird bio, Inc. is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. Its oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. Its oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.
